NcXHF

PEMMARAJU AND MOLITERNO
13. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of
JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;
111:5109-5117.
14. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic
activating mutation in myelofıbrosis with myeloid metaplasia. PLoS
Med. 2006;3:e270.
15. Fleischman AG, Maxson JE, Luty SB, et al. The CSF3R T618I mutation
causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic
JAK inhibition. Blood. 2013;122:3628-3631.
16. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identifıcation
of high-risk polycythemia vera patients based on JAK2(V617F)
allele burden. Leukemia. 2007;21:1952-1959.
17. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of
calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:
2379-2390.
18. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative
neoplasms with nonmutated JAK2. N Engl J Med. 2013;
369:2391-2405.
19. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in
chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;
368:1781-1790.
20. Nielsen C, Birgens HS, Nordestgaard BG, et al. Diagnostic value of JAK2
V617F somatic mutation for myeloproliferative cancer in 49 488 individuals
from the general population. Br J Haematol. 2013;160:70-79.
21. Braunstein EM, Moliterno AR. Back to biology: new insights on inheritance
in myeloproliferative disorders. Curr Hematol Malig Rep. 2014;
9:311-318.
22. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor
for the development of myeloproliferative neoplasms. Nat Genet. 2009;
41:446-449.
23. Zangari M, Fink L, Tolomelli G, et al. Could hypoxia increase the prevalence
of thrombotic complications in polycythemia vera? Blood Coagul
Fibrinolysis. 2013;24:311-316.
24. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545
patients with contemporary polycythemia vera: An international study.
Leukemia. 2013;27:1874-1881.
25. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast
transformation in molecularly annotated essential thrombocythemia,
polycythemia vera, and myelofıbrosis. Blood. 2014;124:2507-2513; quiz
2615.
26. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia:
2015 update on diagnosis, risk-stratifıcation and management. Am J Hematol.
2015;90:162-173.
27. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defınes
subtypes of essential thrombocythemia with substantially different
clinical course and outcomes. Blood. 2014;123:1544-1551.
28. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic
factors in the classic BCR/ABL-negative myeloproliferative disorders.
Leukemia. 2008;22:905-914.
29. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict
survival in 867 World Health Organization-defıned essential thrombocythemia
at diagnosis: a study by the International Working group on
Myelofıbrosis Research and Treatment. Blood. 2012;120:1197-1201.
30. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of
an International Prognostic Score of thrombosis in World Health
Organization-essential thrombocythemia (IPSET-thrombosis). Blood.
2012;120:5128-5133; quiz 5252.
31. Pemmaraju N, Moliterno AR, Williams DM, et al. The quantitative
JAK2 V617F neutrophil allele burden does not correlate with thrombotic
risk in essential thrombocytosis. Leukemia. 2007;21:2210-2212.
32. Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does
not modify the IPSET score for predicting the risk of thrombosis among
1150 patients with essential thrombocythemia. Blood. 2014;124:2611-
2612.
33. Stein BL, Williams DM, Wang NY, et al. Sex differences in the JAK2
V617F allele burden in chronic myeloproliferative disorders. Haematologica.
2010;95:1090-1097.
34. Marchioli R, Finazzi G, Landolfı R, et al. Vascular and neoplastic risk in
a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:
2224-2232.
35. Vannucchi AM. How I treat polycythemia vera. Blood. 2014;124:3212-
3220.
36. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and
intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22-
33.
37. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and
MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis:
a report on 241 cases. Blood. 2008;111:4922-4929.
38. Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms
in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
Blood. 2012;120:4921-4928.
39. Pemmaraju N, Hamilton JP, Cameron AM, et al. Abdominal venous
thrombosis presenting in myeloproliferative neoplasm with JAK2
V617F mutation: a case report. J Med Case Rep. 2012;4921-49216:102.
40. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a
prognostic marker in primary myelofıbrosis: applicability at the time of diagnosis
and later during disease course. Blood. 2009;113:4171-4178.
41. Stein BL, Williams DM, O’Keefe C, et al. Disruption of the ASXL1 gene
is frequent in primary, post-essential thrombocytosis and postpolycythemia
vera myelofıbrosis, but not essential thrombocytosis or
polycythemia vera: analysis of molecular genetics and clinical phenotypes.
Haematologica. 2011;96:1462-1469.
42. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in
myeloproliferative neoplasms. Leukemia. 2009;23:2183-2186.
43. Scott LM, Rebel VI. JAK2 and genomic instability in the myeloproliferative
neoplasms: a case of the chicken or the egg? Am J Hematol. 2012;
87:1028-1036.
44. Alvarez-Larrán A, Bellosillo B, Martínez-Aviles L, et al. Postpolycythaemic
myelofıbrosis: frequency and risk factors for this complication in
116 patients. Br J Haematol. 2009;146:504-509.
45. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients
with polycythemia vera: the impact of JAK2 (V617F) allele burden and
leukocytosis on fıbrotic or leukemic disease transformation and vascular
complications. Leukemia. 2010;24:1574-1579.
46. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic
chronic myeloproliferative disorders: actuarial probability
and main characteristics in a series of 218 patients. Acta Haematol. 1991;
85:124-127.
47. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia
vera: an analysis of 1638 patients enrolled in a prospective observational
study. Blood. 2005;105:2664-2670.
48. Cervantes F, Pereira A. Prognostication in primary myelofıbrosis. Curr
Hematol Malig Rep. 2012;7:43-49.
49. Stein BL, Moliterno AR. Primary myelofıbrosis and the myeloproliferative
neoplasms: the role of individual variation. JAMA. 2010;303:2513-
2518.
50. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system
for primary myelofıbrosis based on a study of the International Working
Group for Myelofıbrosis Research and Treatment. Blood. 2009;113:
2895-2901.
51. Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic
burden among myeloproliferative neoplasm patients: retrospective
assessment in 1470 patients. Blood. 2014;123:3803-3810.
144 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook